{"DataElement":{"publicId":"6842050","version":"1","preferredName":"Aglatimagene Besadenovec Injection Administered Date","preferredDefinition":"The date of Adv-tK injection.","longName":"ADV_TK_INJECT_DT","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"6841861","version":"1","preferredName":"Aglatimagene Besadenovec Injection Method of Administration Administered","preferredDefinition":"An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response._The technique of administration of a pharmaceutical product by introducing it into the body, usually after puncturing the skin; one or more of a variety of routes may be specified, the most common being intravenous, intramuscular and subcutaneous._The act of having given something (e.g., a medication or test).","longName":"6841996v1.0:6841998v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"6841996","version":"1","preferredName":"Aglatimagene Besadenovec","preferredDefinition":"An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.","longName":"C73996","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aglatimagene Besadenovec","conceptCode":"C73996","definition":"An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F134498-C7B5-44A6-E053-F662850A6F70","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6841998","version":"1","preferredName":"Injection Method of Administration Administered","preferredDefinition":"The technique of administration of a pharmaceutical product by introducing it into the body, usually after puncturing the skin; one or more of a variety of routes may be specified, the most common being intravenous, intramuscular and subcutaneous.:The act of having given something (e.g., a medication or test).","longName":"C149592:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Injection Method of Administration","conceptCode":"C149592","definition":"The technique of administration of a pharmaceutical product by introducing it into the body, usually after puncturing the skin; one or more of a variety of routes may be specified, the most common being intravenous, intramuscular and subcutaneous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F134498-C7C7-44A6-E053-F662850A6F70","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F1136CE-B1EB-3C81-E053-F662850AC2AF","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018550","version":"1","preferredName":"Date","preferredDefinition":"The date on which an observation was made or an event occurred.","longName":"DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"MM/DD/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"B54EF112-5457-674A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-28","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-28","modifiedBy":"ZHWENDY","dateModified":"2023-12-12","changeDescription":"8/3/17 tt added Diagnosis CSI. 6/20/17 jk transferred to NCI Standards per confirmation by Brian Campbell as part of Round 5 finalization task, added reg status.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280726","version":"1","longName":"Evaluations","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Date of Adv-tK Injection","type":"Preferred Question Text","description":"Date of Adv-tK Injection","url":null,"context":"ABTC"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F130096-434C-3D07-E053-F662850AD1B2","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeDescription":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}